-
Posted by
Two Blokes Jul 24 -
Filed in
Stock
-
10 views
Abivax shares surged 500% after positive phase 3 results for obefazimod in moderate-to-severe ulcerative colitis, achieving significant clinical remission at 8 weeks induction period. Both ABTECT-1 and ABTECT-2 studies showed statistically significant results, supporting obefazimod's differentiated safety and efficacy profile as a first-in-class oral miR-124 enhancer. The next major catalyst is the 44-week maintenance trial data, expected in Q2 2026, which could enable a New Drug Application filing of obefazimod in H2 2026.
